Xintela taking EQSTEM, a stem cell product for horses, towards the market

In a recently completed study in horses, the stem cell product EQSTEM® shows significantly reduced lameness in horses with osteoarthritis (OA) due to joint injury, indicating that this product can reduce joint pain and improve joint function. Xintela is now taking EQSTEM further to the animal health market and will, in dialogue with EMA (European Medicines Agency), determine what additional information is needed for an approval of EQSTEM.

Xintela has previously shown that the company's integrin α10β1-selected stem cells from horses, EQSTEM, which is the equivalent of XSTEM® for humans, have a therapeutic effect on cartilage and bone in an OA model in horses. In order to obtain increased information about the functional effect of the stem cells, Xintela also studied the lameness of horses with OA after a joint injury. The degree of lameness is a measure of the degree of pain and impaired function in the injured joint. The study was conducted in collaboration with Professor Casper Lindegaard and his research team at the Department of Veterinary Clinical Sciences at the University of Copenhagen. The results showed that an injection of EQSTEM in a joint with OA after a joint injury, significantly reduced the lameness of the horses compared to untreated horses with a similar injury.


"Xintela has performed research and development with equine stem cells since the start of the company and we have been very successful with our horse studies. The results have strongly supported the development of our human product XSTEM for treatment of OA, which will now be tested in clinical trials on humans, and also build the foundation for the stem cell product EQSTEM for horses. The positive results, the large need for an effective OA therapy for horses and that EQSTEM can reach the market significantly earlier than the product XSTEM for humans, has led to our decision to further develop EQSTEM in collaboration with Professor Lindegaard", says Xintela's CEO Evy Lundgren-Åkerlund.


Professor Casper Lindegaard comments: "Osteoarthritis in horses is very common and today there are no effective treatment options. The positive treatment effect that Xintela's horse product EQSTEM shows on the lameness of horses with osteoarthritis is very convincing and shows that EQSTEM has great potential to be an effective therapy. We are very much looking forward to the continued collaboration with Xintela to bring EQSTEM further towards the market".

Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: +46 46 275 65 00
Email: [email protected]
Medicon Village
223 81 Lund, Sweden
www.xintela.se


About Xintela
Xintela develops innovative and patent protected cell therapies and targeted cancer therapies based on the marker technology platform XINMARK®. The platform is built on specific cell surface proteins (integrins) and more than 25 years of research and development. Xintela uses the marker technology to select and quality assure stem cells (XSTEM) to develop stem cell therapies for diseases that today lack efficient treatment options, including the joint disease osteoarthritis (OA). Xintela has built an in-house GMP-facility for manufacturing of stem cell products and is preparing a First in Human clinical study on patients with knee OA. In the oncology program, Xintela develops antibody-based therapies for treatment of aggressive tumors including glioblastoma and triple-negative breast cancer. Xintela is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, [email protected]

Xintela AB Delårsrapport januari - september 2021

Xintela AB Delårsrapport januari - september 2021


Xintela AB Interim report January - September 2021


Xintela AB Interim report January - September 2021


Xintela erhåller lån om 9 MSEK

Xintela AB meddelar idag att bolaget erhåller ett lån om 9 MSEK


Uppdatering av Xintelas och Targintas status och strategi

Xintela utvecklar stamcellsbaserade behandlingar med fokus på artros och svårläkta bensår samt, genom det helägda dotterbolaget Targinta, riktade antikroppsbaserade behandlingar för aggressiv cancer. Verksamheterna är inriktade på sjukdomar där det medicinska behovet är mycket stort och effektiva behandlingar idag saknas. Ett gediget prekliniskt arbete har lagt grunden för Xintelas och Targintas fortsatta utvecklingsarbete mot kliniska studier och kommersialisering.
En sammanställning över respektive bolags utvecklingsprojekt, projektens status samt strategier och prioriteringar, presenteras nedan.


Update on status and strategy for Xintela and Targinta

Xintela develops stem cell-based treatments with a focus on osteoarthritis and difficult-to-heal leg ulcers and, through its wholly owned subsidiary Targinta, targeted antibody-based treatments for aggressive cancers. We are focused on diseases where there is a high medical need and where effective treatments are lacking today. Solid preclinical R&D has laid the foundation for Xintela's and Targinta's continued progress toward clinical studies and commercialisation.
A summary of each company's development pipeline, the status of each of these projects, and future strategy and priorities, is presented below.


Ny styrelse har utsetts i Targinta AB

Xintela AB meddelar att ny styrelse har utsetts i Targinta AB, ett helägt dotterbolag till Xintela AB. Jeffrey Abbey, Karin Wingstrand och Maarten de Château har valts som nya styrelseledamöter. Gregory Batcheller, styrelseordförande, och Evy Lundgren-Åkerlund är sedan tidigare medlemmar i Targintas styrelse. Gunnar Telhammar avgår som styrelseledamot i Targinta.


New board of directors appointed in Targinta AB

Xintela AB announces the appointment of a new board of directors in Targinta AB, a wholly-owned subsidiary of Xintela. Jeffrey Abbey, Karin Wingstrand and Maarten de Château have been appointed as new board members. Gregory Batcheller, chairman, and Evy Lundgren-Åkerlund are already members of the board of Targinta. Gunnar Telhammar resigns as board member.


Xintela tar EQSTEM, en stamcellsprodukt för hästar, mot marknaden

I en nyligen avslutad studie på hästar visar stamcellsprodukten EQSTEM® signifikant minskad hälta hos hästar med artros till följd av en ledskada, vilket indikerar att produkten kan minska smärtan i leden och förbättra ledens funktion. Xintela tar nu EQSTEM vidare mot marknaden och kommer i dialog med EMA (European Medicines Agency) fastställa vilken kompletterande information som behövs för ett godkännande.


Xintela taking EQSTEM, a stem cell product for horses, towards the market

In a recently completed study in horses, the stem cell product EQSTEM® shows significantly reduced lameness in horses with osteoarthritis (OA) due to joint injury, indicating that this product can reduce joint pain and improve joint function. Xintela is now taking EQSTEM further to the animal health market and will, in dialogue with EMA (European Medicines Agency), determine what additional information is needed for an approval of EQSTEM.


Targinta väljer läkemedelskandidat för trippelnegativ bröstcancer

Det prekliniska onkologibolaget Targinta har valt sin första läkemedelskandidat, TARG10, en terapeutisk antikropp riktad mot målproteinet integrin a10b1. TARG10 har visat kraftfulla effekter både på cancerceller och i prekliniska tumörmodeller, med minskad tumörtillväxt och minskad metastasering i trippelnegativ bröstcancer.


Targinta selects lead drug candidate for triple-negative breast cancer

The preclinical stage oncology biotech company Targinta has selected its first lead drug candidate, TARG10, a therapeutic antibody targeting integrin a10b1. TARG10 has shown strong activity on cancer cells and in preclinical tumor models, with significant inhibitory effects on both growth and metastasis in triple-negative breast cancer models.


Xintela breddar klinisk utveckling av stamcellsprodukten XSTEM

Lund, Sverige, 30 september 2021 - Xintela meddelar att bolaget utökar det kliniska utvecklingsarbetet av sin stamcellsprodukt XSTEM till nästa valda indikation, venösa bensår, den vanligaste formen av svårläkta (kroniska) sår hos människor. Ett vetenskapligt rådgivningsmöte med Läkemedelsverket har framgångsrikt genomförts och arbetet med att ta fram dokumentation för en ansökan om klinisk studie på venösa bensår har initierats.


Xintela to expand clinical development of stem cell product XSTEM

Lund, Sweden, September 30 2021 - Xintela announces it will expand clinical development of its stem cell product XSTEM to the next chosen indication venous leg ulcers, the most common type of difficult-to-heal (chronic) wounds in humans. A scientific advice meeting with the Swedish Medical Products Agency (MPA) has been successfully completed and preparation of clinical documentation for the clinical study application has been initiated.




Xintela tecknar avtal med australiensisk CRO för klinisk studie

Xintela meddelar idag att företaget har tecknat ett avtal med GreenLight Clinical, en australiensisk CRO (Contract Research Organization) för att genomföra Xintelas första kliniska studie i människa med stamcellsprodukten XSTEM.


Xintela signs with Australian CRO for clinical study

Xintela announces today that the company has signed a contract with GreenLight Clinical, an Australian Contract Research Organisation (CRO) to conduct Xintela's First-in-Human study using the stem cell product XSTEM.


Kommuniké från extra bolagsstämma i Xintela

Xintela 5 juli 2021 - Idag hölls en extra bolagsstämma i Xintela AB. Nedan följer en sammanfattning av de beslut som fattades. Samtliga beslut fattades med erforderlig majoritet.


Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Nybrogatan 34
Box 5216
102 45 Stockholm

08-692 21 90

Om beQuoted